ACT Stock Overview
Develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 6/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
AlzChem Group AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €41.80 |
52 Week High | €52.80 |
52 Week Low | €19.40 |
Beta | 1.01 |
11 Month Change | -18.68% |
3 Month Change | -8.53% |
1 Year Change | 110.05% |
33 Year Change | 72.02% |
5 Year Change | 113.27% |
Change since IPO | 55.45% |
Recent News & Updates
Recent updates
Shareholder Returns
ACT | DE Chemicals | DE Market | |
---|---|---|---|
7D | -3.7% | 5.4% | 2.8% |
1Y | 110.1% | 7.4% | 8.6% |
Return vs Industry: ACT exceeded the German Chemicals industry which returned 7.4% over the past year.
Return vs Market: ACT exceeded the German Market which returned 8.6% over the past year.
Price Volatility
ACT volatility | |
---|---|
ACT Average Weekly Movement | 7.3% |
Chemicals Industry Average Movement | 4.5% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 11.9% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ACT's share price has been volatile over the past 3 months.
Volatility Over Time: ACT's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1908 | 1,607 | Andreas Niedermaier | www.alzchem.com |
AlzChem Group AG, together with its subsidiaries, develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The company offers dietary supplements under the Creapure and Alipure brands; preparation of guanidinoacetic acid as a nutritional feed additives under the Creamino brand; creatine dietary supplements under the LIVADUR brand; products for pharmaceuticals under the Bioselect brand; curing agents, including accelerators for use in adhesives, powder coatings, printed circuit boards, and composites under the DYHARD name; and silicon nitride for ceramics, and electronics and solar applications under the SILZOT brand.
AlzChem Group AG Fundamentals Summary
ACT fundamental statistics | |
---|---|
Market cap | €426.39m |
Earnings (TTM) | €46.34m |
Revenue (TTM) | €556.77m |
9.2x
P/E Ratio0.8x
P/S RatioIs ACT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ACT income statement (TTM) | |
---|---|
Revenue | €556.77m |
Cost of Revenue | €218.93m |
Gross Profit | €337.84m |
Other Expenses | €291.50m |
Earnings | €46.34m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
Earnings per share (EPS) | 4.55 |
Gross Margin | 60.68% |
Net Profit Margin | 8.32% |
Debt/Equity Ratio | 29.3% |
How did ACT perform over the long term?
See historical performance and comparison